not quite out of the blue - it's already well known that AHZ are investigating further applications for CardioCel such as knee, hernia, pelvic floor apps but that program stretches out to 2020? not quite sure of the order but AHZ provided a timeline in one of their announcements a year or so ago. All these things will improve AHZ's situation over time provided the current application provides the readies - a lot hinges on the success of the current program (obvious), and the market is hungry for guidance. AHZ has big (relatively) expenses so some big dollars are needed to cover it. If CardioCel brings home the bacon, I'm sure there'll be sp improvement, big surprises are not needed IMO, merely pleasant ones.
Blue Sky, page-22
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
0.000(0.00%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $17.70 | $58.64K | 3.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 109 | $18.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.10 | 700 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |